Paclitaxel-based DCB incorporates new characteristics including lower balloon drug surface concentration and particulate counts.

Vascular Nanotransfer Technologies president and CEO John Williams said the company’s proprietary balloon coating technology is designed for enhanced drug delivery and superior coating characteristics.

"VNT has achieved tissue levels of paclitaxel that are comparable to devices with proven clinical efficacy but has done so with a device that has superior coating characteristics along with a lower concentration of paclitaxel per surface area," Williams added.

"Now we have a high-performing paclitaxel nano-carrier based DCB with strong in vivo test results.

"We expect to begin patient enrollment for VNT’s First-In-Man clinical trial in early 2013."